OMIC Singular Genomics Systems, Inc. revenue, earnings and financials
For the quarter ended September 30, 2024, Singular Genomics Systems, Inc. reported revenue of $406K (down 12.1% from a year earlier), net income of −$16.8M and diluted EPS of −$6.72; over the last four quarters revenue was $2.67M and net income −$86.3M; for the fiscal year ended December 2023 revenue was $2.91M, up 280.5% on the year before.
OMIC annual revenue and earnings
- Fiscal year ended Dec 2023: revenue $2.91M, gross profit −$558K, operating income −$103M, net income −$94.8M (margin -3257.3%), EPS −$1.30
- Fiscal year ended Dec 2022: revenue $765K, gross profit −$24.0K, operating income −$93.5M, net income −$90.9M (margin -11879.6%), EPS −$1.28
- Fiscal year ended Dec 2021: revenue $0, gross profit $0, operating income −$61.3M, net income −$98.8M (margin n/a), EPS −$2.10
OMIC quarterly revenue and earnings
- Quarter ended Sep 30, 2024: revenue $406K (down 12.1% year over year), net income −$16.8M, EPS −$6.72
- Quarter ended Jun 30, 2024: revenue $737K (up 45.9% year over year), net income −$21.3M, EPS −$8.57
- Quarter ended Mar 31, 2024: revenue $442K (down 48.8% year over year), net income −$25.0M, EPS −$0.34
- Quarter ended Dec 31, 2023 (from the annual report): revenue $1.08M (up 41.3% year over year), net income −$23.2M, EPS $18.86
- Quarter ended Sep 30, 2023: revenue $462K, net income −$22.4M, EPS −$9.25
- Quarter ended Jun 30, 2023: revenue $505K, net income −$25.6M, EPS −$10.58
- Quarter ended Mar 31, 2023: revenue $863K, net income −$23.6M, EPS −$0.33
- Quarter ended Dec 31, 2022 (from the annual report): revenue $765K, net income −$21.1M, EPS −$0.30
- Quarter ended Sep 30, 2022: revenue $0, net income −$23.8M, EPS −$0.33
- Quarter ended Jun 30, 2022: revenue $0, net income −$24.0M, EPS −$0.34
- Quarter ended Mar 31, 2022: revenue $0, net income −$22.0M, EPS −$0.31
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$19.8M, EPS $1.38
- Quarter ended Sep 30, 2021: revenue n/a, net income −$17.6M, EPS −$0.25
- Quarter ended Jun 30, 2021: revenue n/a, net income −$37.5M, EPS −$1.18
- Quarter ended Mar 31, 2021: revenue n/a, net income −$23.9M, EPS −$2.05
OMIC cash flow, buybacks and dividends
- Fiscal year ended Dec 2023: operating cash flow −$73.6M, share buybacks $19.0K
- Fiscal year ended Dec 2022: operating cash flow −$87.1M, share buybacks $450K
- Fiscal year ended Dec 2021: operating cash flow −$51.7M, share buybacks n/a
OMIC balance sheet
- Sep 30, 2024: cash $52.6M, total assets $187M, total liabilities $63.3M, shareholders' equity $123M, long-term debt $5.17M
- Jun 30, 2024: cash $30.1M, total assets $220M, total liabilities $82.3M, shareholders' equity $138M, long-term debt $6.36M
- Mar 31, 2024: cash $24.1M, total assets $239M, total liabilities $82.4M, shareholders' equity $157M, long-term debt $7.63M
- Dec 31, 2023: cash $16.2M, total assets $265M, total liabilities $86.5M, shareholders' equity $179M, long-term debt $8.90M
- Sep 30, 2023: cash $33.3M, total assets $285M, total liabilities $85.5M, shareholders' equity $199M, long-term debt $10.2M
- Jun 30, 2023: cash $74.8M, total assets $284M, total liabilities $65.6M, shareholders' equity $218M, long-term debt $10.1M
- Mar 31, 2023: cash $129M, total assets $305M, total liabilities $65.1M, shareholders' equity $240M, long-term debt $10.1M
- Dec 31, 2022: cash $74.3M, total assets $328M, total liabilities $67.7M, shareholders' equity $260M, long-term debt $10.1M
What is OMIC's revenue?
Singular Genomics Systems, Inc. reported $2.67M of revenue over its last four quarters, through September 30, 2024.
Is OMIC profitable?
No. Singular Genomics Systems, Inc. lost $86.3M over the last four quarters.
What is OMIC's EPS?
Diluted earnings per share over the last four quarters were $3.23; −$6.72 in the latest quarter.